Cancer vaccine trial tests immune system boost for rare lymphoma
NCT ID NCT01209871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main goal was to find the safest dose and check for side effects, with a secondary look at whether the vaccine sparked an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized DNA vaccine made from the patient's own cancer cells
What this could lead to
If it works, this could point toward a way to train the immune system to fight lymphoma without immediate chemotherapy.
What could go wrong
This is a very early, small phase 1 trial with only 9 participants. It is designed mainly to check safety, not yet to prove the vaccine works. Many early vaccines fail to show strong enough immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States